Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176884 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CA1CA2KDM4EGAA | |
| SCHEMBL2418864 | 0.77 | ALDH1A1 (0.36) | KDM4EGAAHTTCYP1A2ALDH1A1 | |
| SCHEMBL2431069 | 0.76 | SIGMAR1 (0.55) | SIGMAR1KDM4EGAAHPGDHTT | |
| SCHEMBL7753428 | 0.73 | SIGMAR1 (0.52) | SIGMAR1KDM4EGAAHPGDHTT | |
| SCHEMBL7401131 | 0.71 | SIGMAR1 (0.53) | SIGMAR1CA1CA2KDM4EGAA | |
| SCHEMBL3068495 | 0.70 | SIGMAR1 (0.49) | SIGMAR1KDM4EGAAALDH1A1 | |
| SCHEMBL20263722 | 0.70 | SIGMAR1 (0.51) | SIGMAR1CA1CA2KDM4EGAA | |
| SCHEMBL6831348 | 0.69 | SIGMAR1 (0.47) | SIGMAR1KDM4EGAAALDH1A1 | |
| SCHEMBL8854244 | 0.69 | KMT2A (0.31) | MAPT | |
| SCHEMBL7411647 | 0.68 | SIGMAR1 (0.49) | SIGMAR1CA1CA2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380494-A1 | COMPOSITION FOR ISOLATING TISSUE | Solventum Intellectual Properties Company (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11827864-B2 | Wipe with a guanidinyl-containing polymer | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-11766386-B2 | Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023067453-A1 | COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230100885-A1 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-03-30 | — | — | US | disclosed |
| WO-2023012556-A1 | COMPOSITION FOR ISOLATING TISSUE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-02-09 | — | — | WO | disclosed |
| US-11123267-B2 | Dental retraction composition with guanidinyl-containing polymer | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210032578-A1 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-02-04 | — | — | US | disclosed |
| EP-3013146-B1 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER | 3M INNOVATIVE PROPERTIES CO (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10844337-B2 | Wipe with a guanidinyl-containing polymer | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20170240591-A1 | LIGAND FUNCTIONALIZED POLYMERS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-08-24 | — | — | US | disclosed |
| US-20170049926-A1 | REMOVABLE FILM FORMING GEL COMPOSITIONS AND METHODS FOR THEIR APPLICATION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-02-23 | — | — | US | disclosed |
| EP-2889625-B1 | LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160115430-A1 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2016-04-28 | — | — | US | disclosed |
| EP-2889625-A1 | LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS | 3M Innovative Properties Company (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2542889-B1 | LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES CO (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130224825-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130217032-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-08-22 | — | — | US | disclosed |
| US-8435776-B2 | Ligand functionalized polymers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110217752-A1 | LIGAND FUNCTIONALIZED POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844337-B2 | Wipe with a guanidinyl-containing polymer | GNPDA1, GDA, PGLS | SIGMAR1 1725/4885CA1 4286/4885CA2 4456/4885 |
| US-11766386-B2 | Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) | GANC, GMPS, MGAM | SIGMAR1 1182/4885CA1 1562/4885CA2 590/4885 |
| US-11123267-B2 | Dental retraction composition with guanidinyl-containing polymer | GMPS, PRMT9, PRMT5 | SIGMAR1 2267/4885CA1 4310/4885CA2 4348/4885 |
| US-20210032578-A1 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER | GNPDA1, GDA, PGLS | SIGMAR1 1725/4885CA1 4286/4885CA2 4456/4885 |
| US-11827864-B2 | Wipe with a guanidinyl-containing polymer | GNPDA1, GDA, PGLS | SIGMAR1 1725/4885CA1 4286/4885CA2 4456/4885 |
| US-20130224825-A1 | LIGAND FUNCTIONALIZED POLYMERS | SELPLG, CD69, SIGLEC7 | SIGMAR1 127/4885CA1 1407/4885CA2 4646/4885 |
| US-20110217752-A1 | LIGAND FUNCTIONALIZED POLYMERS | SELPLG, CD69, SIGLEC7 | SIGMAR1 127/4885CA1 1407/4885CA2 4646/4885 |
| US-20170240591-A1 | LIGAND FUNCTIONALIZED POLYMERS | SELPLG, CD69, SIGLEC7 | SIGMAR1 127/4885CA1 1407/4885CA2 4646/4885 |
| US-20230100885-A1 | WIPE WITH A GUANIDINYL-CONTAINING POLYMER | GNPDA1, GDA, PGLS | SIGMAR1 1725/4885CA1 4286/4885CA2 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.